Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: a systematic review and meta-analysis of randomized controlled trials
Persistently elevated glucagon-like peptide-1 levels among critically ill surgical patients after sepsis and development of chronic critical illness and dismal long-term outcomes
JAMA (2025)
Biologic Acitivity of Mitochondrial Metabolites on Aging and Age-Related Hearing Loss
At Vista Innovate, we see a massive opportunity for R&D leaders to bridge the Satiety-Biology Gap through three technical levers: The Kinetic Shift: Leveraging Hydrolyzed Peptides for faster absorption and "gentle digestion." The Leucine Trigger: Engineering high-density, low-volume formats that actually flip the muscle protein synthesis (MPS) switch
Similarly, changes in albuminuria appear as the strongest predictor of major kidney outcomes according to the Parameter Response Efficacy (PRE) score, an algorithm integrating several biomarkers of renal adverse events, as treatment with liraglutide resulted in a 16.2% estimated relative risk reduction (RRR) of kidney outcomes, similar to the observed RRR of 15.5%, which was mainly driven by UACR changes (RRR 13.2%) [15]